Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy

Abstract

Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase is over-expressed in numerous human tumors, which plays pivotal roles in cellular signal transduction, and it is involved in a variety of tumor cellular behaviors such as proliferation, metastasis, angiogenesis and so on.Many investigations have indicated that tumor growth can be suppressed by inhibiting EGFR tyrosine kinase activity.Currently, several EGFR tyrosine kinase inhibitors are in clinical trial stage.

Key words: phacology, epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors, cancer therapy, clinical trial

CLC Number:

R966
R979.1

LI Zhe, YUAN Shou-Jun. Application of epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(4): 361-364.

References

1 Kathryn SK, Brian JD.Protein tyrosine kinases and cancer[J]. Biochimica Biophysica Acta, 1997;1333(3):217-48
2 Fortunato C, Giampaolo T.A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor[J].Clin Cancer Res, 2001;7(10):2958-70
3 BosM, Mendelsohn J, Kim YM, Albanell J, Fry DW, Basellga J, et al.PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor trceptor activation and inhibits growth of cancer cells in a receptor number-dependent manner[J].Clin Cancer Res, 1997;3(11):2099-106
4 Woodburn JR, Barker AJ.4-Anilinoquii-nazolines-a potential new therapy for major human solid tumors overexpressing the EGF receptor[J].Br J Cancer, 1996;74(1):18-24
5 Di GE, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, et al.Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (‘Iressa'), an epidermal growth factor receptor tyrsine kinase inhibitor, in head and neck squamous carcinoma cells[J].J Cell Physiol, 2003;195(1):139-50
6 Ciardiello F, Caputo R, Bianco R, Damianco V, Pomatico G, De Placido S, et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive ty rosine kinase inhibitor[J].Clin Cancer Res, 2000;6(5):2053-63
7 Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C.EGFR blockade with ZD1839 (“ Iressa”) potentiates the antitumor effects of single and mul-tiple fractions of ionzing radiation in human A431 squamous cell carcinoma, Epidermal growth factor receptor[J].Int J Radiat Oncol Biol Phys, 2003;55(3):713-23
8 Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al.Phase Ⅰ safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor ty rosine kinase inhibitor, in patients with five selected solid tumor types[J].J Clin Oncol, 2002;20(21): 4292-302
9 Miller VA, Johnson D, Heelan RT, Pizzo BA, Perez WJ, Bass A, et al.A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small lung cancer (NSLC)[J].Proc Am Soc Clin Oncol, 2001;21:326
10 Perter T, Guido B, Elisabeth B, Giorgio C, Pascal F, PaulM, et al.Tyrosine Kinase Inhibitors:From Rational Design to Clinical Trials[J].Med Res Rev, 2001;21(6):499-512
11 Myers JN, Holsinger FC, Bekele BN, Li E, Jasser SA, Killion JJ, et al.Targeted molecular therapy for oral cancer with epidermal growth factor blockade:a preliminary report[J].Arch Otolaryngol Head Neck Surg, 2002;128(8):875-9
12 Mellinggoff IK, Tran C, Sawyers CL.Growth inhibitory efects of the dual ErbB1/ErbB2 ty rosine kinase inhibitor PKI-166 on human prostate cancer xenografts[J].Cancer Res, 2002;62 (18):5254-9
13 Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ.Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice[J].Clin Cancer Res, 2003;9(3):1200-10
14 Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al.Induction of apoptosis and cell cy cle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase[J].Cancer Res, 1997;57(21):4838-48
15 Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, et al.Inhibition of epidermal growth factor receptor-associated tyrosine phosphory-lation in human carcinomas with CP-358, 774:dynamics of receptor inhibition in situ and antitumor effects in athymic mice [J].Pharmacol Exp Ther, 1999;291(2):739-48
16 Siu LL, Hidalgo M, Nemunaitis J, Rizzo J, Moczygemba J, Eckhardt SG, et al.Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358774:a phase I and pharmacokinetic (PK) study[C].Proc Am Soc Clin Oncol, 1999;18:388
17 Finkler N, Gordon A, Crozier M, Edwards R, Figueroa J, Garcia A, et al.Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma[C].Proc Am Soc Clin Oncol, 2001;21:208
18 Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, et al.A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)[C].Proc Am Soc Clin Oncol, 2001;21:310
19 Sherwood V, Bridges AJ, Denny WA, Rewcastle GW, Smaill JB, Fry DW.Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD 158780 and a new irreversible inhibitor, PD 183805[C].Proc Am Assoc Cancer Res, 1999;40:723
20 Driscoll D, Steinkampf R, Patmore S, Elliott W, Klohs W. Effect of epidermal growth factor receptor tyrosine kinase inhibitor PD183805 on vascular endothelial growth factor secretion from several tumor models[C].Proc Am Assoc Cancer Res, 1999;40:121
21 Greenberger LM, Discafani C, Wang YF, Tsou HR, Overbeek EG, Nilakantan R, et al.388 EKB-569:a new irreversible inhibitor of epidermal growth factor receptor tyrsine kinase for the treatment of cancer[J].Clin Cancer Res, 2000;6(suppl):388-9
22 Manuel H, Charles E, Eric KR, Jody KN, Kim J, Joscph B, et al.Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors[C].Am Soc Clin Oncol, 2002:65

[1]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[2]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[3]	DAI Jiahui, SUN Sijia, XIE Xuefeng. Quality management and indicator system for clinical trials of medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
[4]	HE Xueru, FU Yuhao, XUN Xuejiao, CUI Yanjun, DONG Zhanjun. Advances in uridine diphosphate glucuronosyltransferase-mediated drug interactions with tyrosine kinase inhibitors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 936-945.
[5]	CHEN Jianfang, LOU Donghua. Design of case report form for oncology clinical trials based on CDASH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
[6]	LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin. Ethical analysis and countermeasures of artificial intelligence application in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
[7]	ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li. Clinical trials of inhalation in pediatric population in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
[8]	LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong. Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
[9]	DENG Kunhong, LIU Yaxin, SUN Yuanyuan, CHEN Wenjing, YANG Nan, HU Zhanqing, CHEN Kaifeng, HUANG Jie, XIANG Yuxia, YANG Guoping. Literature analysis of the design and results of the First-In-Human clinical trials of drugs from 2009 to 2020 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 77-85.
[10]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[11]	SHE Zhihua, CHEN Zhou, LIANG Songyue. Construction of informatization system of drug clinical trials ethical review based on cloud architecture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
[12]	SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan. Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
[13]	OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin. Ethical issues and countermeasures of early phase trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
[14]	LOU Anqi, YU Junxian, CHENG Zizhao, SU Qiang. Bruton tyrosine kinase inhibitors and refractory mantle cell lymphoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 680-686.
[15]	HUANG Lihong, WANG Ling, YAN Fangrong, WEI Zhaohui, ZHAO Yang, XIA Jielai, CHEN Feng. New perspectives on the principle of intention to treat in clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 449-453.